Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Sarcoma: early-phase trial registry
8 of 13 indexed Metastatic Sarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 8 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Metastatic Sarcoma: 13 US clinical trials tracked, 8 recruiting.
Metastatic Sarcoma is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition metastatic-sarcoma
OPEN 8 | RECR 62% | LATE 0 | EARLY 7 | RANK #1315 | SPON 3
Volume-matched condition peers
Nearest open-share peer: High Risk Myelodysplastic Syndrome (62% recruiting · 13 trials)
Metastatic Sarcoma lists 8 open slots (62% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Sarcoma is recruiting above its size-band peers.
8 of 13 indexed trials (61.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Sarcoma research.
M.D. Anderson Cancer Center accounts for 3 of 13 trials (23.1%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Sarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 13 trials that report a genuine target (sentinel values excluded). 13 of those (100%) plan for fewer than 100 participants.
-
Metastatic Sarcoma research is mostly interventional.
12 interventional and 1 observational studies make up this index (92.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Intravital Microscopy in Human Solid Tumors
Mayo Clinic
NCT03823144
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06796543
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
M.D. Anderson Cancer Center
NCT04693377
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
National Cancer Institute (NCI)
NCT05711615
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Lantheus Medical Imaging
NCT06298916
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
M.D. Anderson Cancer Center
NCT04199026
A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma
Fred Hutchinson Cancer Center
NCT05835154
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
Ann & Robert H Lurie Children's Hospital of Chicago
NCT06235125
Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study
M.D. Anderson Cancer Center
NCT04430725
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
National Cancer Institute (NCI)
NCT04595747
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
Jonsson Comprehensive Cancer Center
NCT04457258
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
Mohammed M Milhem
NCT01106872
α-TEA in Advanced Cancer
Providence Health & Services
NCT02192346
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Sarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Sarcoma page
13 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Metastatic Sarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Metastatic Sarcoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Sarcoma condition card totals 13 registered trials; most-linked intervention Computed Tomography; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.